Mesenchymal stem cell therapy for liver fibrosis/cirrhosis

Area of Science:

• Hepatology and Regenerative Medicine

Background:

• Liver fibrosis is a common consequence of chronic liver diseases, often progressing to cirrhosis.
• Current treatments for advanced liver fibrosis and cirrhosis are limited, with liver transplantation being the only definitive option.
• Alternative therapeutic strategies are urgently needed due to the limitations of liver transplantation.

Purpose of the Study:

• To review the properties and clinical applications of mesenchymal stem cells (MSCs) in treating liver fibrosis and cirrhosis.
• To discuss the immune-modulatory mechanisms underlying MSC-based therapy for liver fibrosis and cirrhosis.

Main Methods:

• Literature review of preclinical and clinical studies on MSC therapy for liver fibrosis.
• Analysis of the immune microenvironment regulation by MSCs in liver fibrosis models.

Main Results:

• MSCs demonstrate therapeutic potential for liver fibrosis and cirrhosis in preclinical and clinical studies.
• Evidence suggests MSCs exert antifibrotic effects primarily through their immune-modulatory properties.
• MSC transplantation influences the immune microenvironment, impacting fibrosis progression.

Conclusions:

• Mesenchymal stem cells (MSCs) represent a promising therapeutic option for liver fibrosis and cirrhosis.
• The immune-modulatory capacity of MSCs is key to their efficacy in treating liver fibrosis.
• Further research into MSC mechanisms can optimize their application in liver disease therapy.